Epidemiology of hepatitis C virus infection in HIV-infected individuals.

Many individuals are infected with both HIV and hepatitis C virus (HCV) infection. More rapid progression of liver disease is seen, higher levels of HCV RNA encourage transmission and sustained virological responses are lower in coinfected patients. The management of these patients is further complicated by potential interactions between antiretroviral therapy and peginterferon and ribavirin.

[1]  F. Carrat,et al.  Severe weight loss in HIV / HCV‐coinfected patients treated with interferon plus ribavirin: incidence and risk factors , 2008, Journal of viral hepatitis.

[2]  V. Soriano,et al.  Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. , 2007, The Journal of infectious diseases.

[3]  J. V. D. van der Meer,et al.  Increase in HCV incidence among men who have sex with men in Amsterdam most likely caused by sexual transmission. , 2007, The Journal of infectious diseases.

[4]  V. Soriano,et al.  Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV‐coinfected patients , 2007 .

[5]  Anne M Johnson,et al.  Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours , 2007, AIDS.

[6]  F. Carrat,et al.  Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? , 2007, Journal of acquired immune deficiency syndromes.

[7]  V. Soriano,et al.  Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. , 2007, The Journal of infectious diseases.

[8]  S. Mehta,et al.  CD4+ T cell-dependent reduction in hepatitis C virus-specific humoral immune responses after HIV infection. , 2007, The Journal of infectious diseases.

[9]  Tulio de Oliveira,et al.  Molecular Epidemiology: HIV-1 and HCV sequences from Libyan outbreak , 2006, Nature.

[10]  J. Montaner,et al.  Histological response to pegIFNα-2a (40KD) plus ribavirin in HIV–hepatitis C virus co-infection , 2006, AIDS.

[11]  K. Mayer,et al.  Prevalence of hepatitis C virus infection among men who have sex with men at a Boston community health center and its association with markers of high-risk behavior. , 2006, AIDS patient care and STDs.

[12]  J. Julian,et al.  Mortality rates and causes of death among all HIV-positive individuals with hemophilia in Canada over 21 years of follow-up. , 2006, Blood.

[13]  C. Katlama,et al.  Efficacy of early treatment of acute hepatitis C infection with pegylated interferon and ribavirin in HIV-infected patients , 2006, AIDS.

[14]  V. Soriano,et al.  Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. , 2006, Journal of viral hepatitis.

[15]  A. Muñoz,et al.  Significant reductions of HIV prevalence but not of hepatitis C virus infections in injection drug users from metropolitan Barcelona: 1987-2001. , 2006, Drug and alcohol dependence.

[16]  G. Kanel,et al.  Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients? , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  C. Rouzioux,et al.  Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy , 2006, AIDS.

[18]  F. Carrat,et al.  Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  A. Mocroft,et al.  Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. , 2005, The Journal of infectious diseases.

[20]  B. Gazzard,et al.  Transmission of Hepatitis C Virus Among HIV-Positive Homosexual Men and Response to a 24-Week Course of Pegylated Interferon and Ribavirin , 2005, Journal of acquired immune deficiency syndromes.

[21]  R. Weber,et al.  Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  N. Voirin,et al.  Prevalence and sexual risk of hepatitis C virus infection when human immunodeficiency virus was acquired through sexual intercourse among patients of the Lyon University Hospitals, France, 1992–2002 , 2005, Journal of viral hepatitis.

[23]  O. Anzala,et al.  Prevalence of HCV and HCV/HIV co-infection among in-patients at the Kenyatta National Hospital. , 2005, East African medical journal.

[24]  H. Jessen,et al.  Treatment of acute hepatitis C infection in HIV‐infected patients: a retrospective analysis of eleven cases , 2005, Journal of viral hepatitis.

[25]  Richard D Moore,et al.  The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection , 2005, Hepatology.

[26]  F. Carrat,et al.  Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. , 2004, JAMA.

[27]  B. Graham,et al.  Prevalence of HCV coinfection in HIV-infected individuals in Nigeria and characterization of HCV genotypes. , 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[28]  D. Vlahov,et al.  The effect of hepatitis C on progression to AIDS before and after highly active antiretroviral therapy , 2004, AIDS.

[29]  E. Delwart,et al.  Frequent hepatitis C virus superinfection in injection drug users. , 2004, The Journal of infectious diseases.

[30]  D. Dieterich,et al.  Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy , 2004, AIDS.

[31]  A. León,et al.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients , 2004, AIDS.

[32]  Sally Caglioti,et al.  Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. , 2004, The New England journal of medicine.

[33]  A. Zanetti,et al.  Lack of Evidence of Sexual Transmission of Hepatitis C among Monogamous Couples: Results of a 10-Year Prospective Follow-Up Study , 2004, American Journal of Gastroenterology.

[34]  E. Ryan,et al.  Neuropsychiatric impact of hepatitis C on advanced HIV , 2004, Neurology.

[35]  P. Marcellin,et al.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. , 2004, Annals of internal medicine.

[36]  V. Soriano,et al.  Treatment of Chronic Hepatitis C in HIV-Infected Patients with Interferon α-2b Plus Ribavirin , 2003 .

[37]  G. Lüchters,et al.  Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection , 2003, The Lancet.

[38]  Y. Lo,et al.  The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. , 2003, Journal of acquired immune deficiency syndromes.

[39]  D. D. Des Jarlais,et al.  Factors associated with hepatitis C virus infection in injection and noninjection drug users in Italy. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[40]  G. Sirera,et al.  Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co‐infected patients , 2003, Journal of viral hepatitis.

[41]  T. F. Rinke de Wit,et al.  Higher prevalence of anti‐HCV antibodies among HIV‐positive compared to HIV‐negative inhabitants of Addis Ababa, Ethiopia , 2002, Journal of medical virology.

[42]  R. Chung,et al.  Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  R. Chung,et al.  Rapidly progressive fibrosing cholestatic hepatitis-hepatitis C virus in HIV coinfection , 2002, American Journal of Gastroenterology.

[44]  R. Chaisson,et al.  Hepatotoxicity associated with nevirapine or efavirenz‐containing antiretroviral therapy: Role of hepatitis C and B infections , 2002, Hepatology.

[45]  C. Trautwein,et al.  Treatment of acute hepatitis C with interferon alfa-2b. , 2001, The New England journal of medicine.

[46]  S. Yerly,et al.  Nosocomial outbreak of multiple bloodborne viral infections. , 2001, The Journal of infectious diseases.

[47]  D. Snydman,et al.  Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[48]  M. Battegay,et al.  Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study , 2000, The Lancet.

[49]  C. Rouzioux,et al.  Detection of hepatitis C virus in the semen of infected men , 2000, The Lancet.

[50]  L. Magder,et al.  The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt , 2000, The Lancet.

[51]  C. Katlama,et al.  Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients , 1999, Hepatology.

[52]  C. Saura,et al.  Screening of viral markers for HIV HBV and HCV infections in blood donors in France and residual risk of viral transmission by blood transfusion. , 1998, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[53]  S. Hammer,et al.  The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. , 1996, The New England journal of medicine.

[54]  A. Phillips,et al.  Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study. , 1995, The Journal of infectious diseases.

[55]  M. Leal,et al.  Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired Hepatitis C , 1995, European Journal of Clinical Microbiology and Infectious Diseases.

[56]  C. Buffet‐Janvresse,et al.  Hepatitis C virus infection in an HIV‐positive population in normandy: Antibodies, HCV RNA and genotype prevalence , 1995, Journal of medical virology.

[57]  J. Alberdi,et al.  Efficacy and safety of α-interferon treatment for chronic hepatitis C in HIV-infected patients , 1995 .

[58]  P. Bacchetti,et al.  Hepatitis C in HIV‐infected patients with and without AIDS: Prevalence and relationship to patient survival , 1994, Hepatology.

[59]  C. Sabin,et al.  The progression of HCV‐associated liver disease in a cohort of haemophilic patients , 1994, British journal of haematology.

[60]  J. Cassuto,et al.  Prevalence of antibody to hepatitis C virus (HCV) in HIV‐1‐infected patients (nice seroco cohort) , 1994, Journal of medical virology.

[61]  A. Pesce,et al.  Opportunistic infections and CD4 lymphocytopenia with interferon treatment in HIV-1 infected patients , 1993, The Lancet.

[62]  E. Concia,et al.  Rapid decline of CD4+ cells after IFNα treatment in HIV-1 infection , 1993, The Lancet.

[63]  J. Goedert,et al.  Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). , 1991, Annals of internal medicine.

[64]  J. Hoofnagle,et al.  Rapidly progressive non-A, non-B hepatitis in patients with human immunodeficiency virus infection. , 1989, Gastroenterology.

[65]  J. Rodríguez-Orengo,et al.  Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. , 2006, Journal of hepatology.

[66]  M. Alter,et al.  Epidemiology of viral hepatitis and HIV co-infection. , 2006, Journal of hepatology.

[67]  M. Bissell.  Detection of HIV-1 and HCV Infections Among Antibody-Negative Blood Donors by Nucleic Acid–Amplification Testing , 2006 .

[68]  J. Montaner,et al.  Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. , 2004, The New England journal of medicine.

[69]  J. Bartlett.  Peginterferon alfa-2a Plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-Co-infected persons , 2004 .

[70]  D. Craven,et al.  Hepatitis C virus and human immunodeficiency virus coinfection in an urban population: low eligibility for interferon treatment. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[71]  V. Soriano,et al.  Treatment of chronic hepatitis C in HIV-infected patients with interferon alpha-2b plus ribavirin. , 2003, AIDS research and human retroviruses.

[72]  L. Simonsen,et al.  Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates. , 1999, Bulletin of the World Health Organization.

[73]  J. Llibre,et al.  Efficacy and safety of alpha-interferon treatment for chronic hepatitis C in HIV-infected patients. HIV-Hepatitis Spanish Study Group. , 1995, The Journal of infection.

[74]  H. Janssen,et al.  Suicide associated with alfa-interferon therapy for chronic viral hepatitis. , 1994, Journal of hepatology.

[75]  G. di Perri,et al.  Rapid decline of CD4+ cells after IFN alpha treatment in HIV-1 infection. , 1993, Lancet.